Procavea Biotech aims to revolutionise the delivery of RNA therapeutics and small molecule drugs. Their innovative and proprietary protein cage platform has the potential to set new standards in molecular medicine, improve existing therapies and address unmet clinical needs. The team's vision is to apply their unique technology to enable the next generation of RNA therapies and precision oncology. Procavea's protein cage technology was developed in the Department of Chemistry and Applied Biosciences at ETH Zurich.